Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Drisapersen Advisory Committee Is Rough Welcome To FDA For Patient Groups

Executive Summary

Advocates counter FDA’s problems with Duchenne muscular dystrophy treatment's trial data using real-life experience.


Related Content

Sarepta's Shadow: BioMarin Mulls Turning The Extraordinary Into A Template
Duchenne Group's Presentation Is Milestone For Patient Involvement
Sarepta's Additional Data Doesn't Sway FDA On Eteplirsen
Sarepta's Duchenne Drug Gains New Panel Review Date, Maybe Optimism
BioMarin's Drisapersen 'Compete Response' Shows FDA Flexibility Still Limited
BioMarin Official Calls Drisapersen AdCom ‘Critical Thinking On Display’
PDUFA VI: FDA Proposes Expanding Sentinel, Real-World Safety Data Sources
Orphan Products Mostly Approved With Regulatory Flexibility, NORD "Catalog" Finds


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts